Skip to main content
. 2022 Mar 18;13:1479. doi: 10.1038/s41467-022-29121-x

Fig. 5. In vivo biodistribution of aCTLA-4 released from F127-g-Gelatin thermosensitive hydrogels.

Fig. 5

a–i Biodistribution of free aCTLA-4-AF647, aCTLA-4-AF647 with 0.45 wt.% F127-g-Gelatin micelles (aCTLA-4 micelle), and aCTLA-4-AF647 with 4.5 wt.% F127-g-Gelatin hydrogel (aCTLA-4 dose equivalent to 162 µg mouse−1) administered into the 1o tumor of C57Bl/6 mice bearing 1o and 2o tumors inoculated with B16F10-OVA 105 cells in 30 μL saline on day 0 and day 4, respectively. a 1o (directly injected) tumor; b LN draining the 1o tumor (1o dLN); c 2o (uninjected) tumor; d LN draining the 2o tumor (2o dLN); e blood; f spleen; g liver; h kidney; i lung. Data are presented as mean ± SEM. n = 4 except (a-i) Free aCTLA-4 groups on day 11 (n = 3) and (a) aCTLA-4/Hydrogel on day 7 (n = 3). *****p < 0.0001, ****p < 0.001, ***p < 0.01, **p < 0.05, and *p < 0.1 with one-way ANOVA using Tukey post-hoc statistical hypothesis. Exact p-values for a–i are reported in Supplementary Table 7. Source data are available in a Source Data file.